Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1991 Jul;32(1):23–29. doi: 10.1111/j.1365-2125.1991.tb05608.x

The influence of Org 10172, a low molecular weight heparinoid, on antipyrine metabolism and the effect of enzyme induction on the response to Org 10172.

A De Boer 1, J C Stiekema 1, M Danhof 1, D D Breimer 1
PMCID: PMC1368488  PMID: 1716140

Abstract

1. We have investigated the effect of repeated s.c. Org 10172 (a low molecular weight heparinoid; Lomoparan) treatment (1000 anti-Xa units twice daily for 5 days) on antipyrine (500 mg orally) metabolism, and the effect of enzyme induction by pentobarbitone (100 mg for 12 days) on the pharmacokinetics and pharmacodynamics of Org 10172 following an intravenous bolus injection of 3250 anti-Xa units. 2. Org 10172 treatment caused a small increase in the formation rates of all antipyrine metabolites (P less than 0.05), while the overall kinetics of antipyrine did not change significantly. 3. Oxidative enzyme induction by pentobarbitone, as demonstrated by an increased clearance of antipyrine, was associated with an increase in the area under the anti-thrombin activity vs time curve (P less than 0.05). No influence was seen on the kinetics of plasma anti-Xa and thrombin generation inhibiting (TGI) activity. 4. The pharmacodynamics of Org 10172, as determined by clotting tests, was not influenced by enzyme induction. 5. The clinical relevance of these observations is likely to be limited.

Full text

PDF
23

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bai S. A., Abramson F. P. Interaction of phenobarbital with propranolol in the dog. 3. Beta blockade. J Pharmacol Exp Ther. 1983 Jan;224(1):62–67. [PubMed] [Google Scholar]
  2. Danhof M., Groot-van der Vis E., Breiner D. D. Assay of antipyrine and its primary metabolites in plasma, saliva and urine by high-performance liquid chromatography and some preliminary results in man. Pharmacology. 1979;18(4):210–223. doi: 10.1159/000137254. [DOI] [PubMed] [Google Scholar]
  3. Danhof M., Verbeek R. M., van Boxtel C. J., Boeijinga J. K., Breimer D. D. Differential effects of enzyme induction on antipyrine metabolite formation. Br J Clin Pharmacol. 1982 Mar;13(3):379–386. doi: 10.1111/j.1365-2125.1982.tb01389.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Danhof M., van Zuilen A., Boeijinga J. K., Breimer D. D. Studies of the different metabolic pathways of antipyrine in man. Oral versus i.v. administration and the influence of urinary collection time. Eur J Clin Pharmacol. 1982;21(5):433–441. doi: 10.1007/BF00542332. [DOI] [PubMed] [Google Scholar]
  5. Doutremepuich C., Castrioto T., De Seze O., Pereira F., Doutremepuich F., Anne M. C., Toulemonde F. What is the best plasmatic activity which could be correlated with the antithrombotic effect of heparin and a low molecular weight heparin fragment? Thromb Res. 1987 Oct 15;48(2):245–251. doi: 10.1016/0049-3848(87)90421-x. [DOI] [PubMed] [Google Scholar]
  6. Ferguson P. W., Anderson J. H., Krieger R. I. Secondary thrombocytopenia following phenobarbital treatments in a rhesus monkey (Macaca mulatta). Lab Anim Sci. 1979 Feb;29(1):94–96. [PubMed] [Google Scholar]
  7. Francis R. J. ELSMOS--an extended least squares modelling system in FORTRAN IV for mini- or micro-computer implementation. Comput Programs Biomed. 1984 Feb-Apr;18(1-2):43–49. doi: 10.1016/0010-468x(84)90022-9. [DOI] [PubMed] [Google Scholar]
  8. Hobbelen P. M., Vogel G. M., Meuleman D. G. Time courses of the antithrombotic effects, bleeding enhancing effects and interactions with factors Xa and thrombin after administration of low molecular weight heparinoid Org 10172 or heparin to rats. Thromb Res. 1987 Dec 1;48(5):549–558. doi: 10.1016/0049-3848(87)90386-0. [DOI] [PubMed] [Google Scholar]
  9. Larsen M. L., Abildgaard U., Teien A. N., Gjesdal K. Assay of plasma heparin using thrombin and the chromogenic substrate H-D-Phe-Pip-Arg-pNA (S-2238). Thromb Res. 1978 Aug;13(2):285–288. doi: 10.1016/0049-3848(78)90016-6. [DOI] [PubMed] [Google Scholar]
  10. Meuleman D. G., Hobbelen P. M., van Dedem G., Moelker H. C. A novel anti-thrombotic heparinoid (Org 10172) devoid of bleeding inducing capacity: a survey of its pharmacological properties in experimental animal models. Thromb Res. 1982 Aug 1;27(3):353–363. doi: 10.1016/0049-3848(82)90082-2. [DOI] [PubMed] [Google Scholar]
  11. Ofosu F. A., Modi G. J., Smith L. M., Cerskus A. L., Hirsh J., Blajchman M. A. Heparan sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways. Blood. 1984 Sep;64(3):742–747. [PubMed] [Google Scholar]
  12. Teien A. N., Lie M. Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III. Thromb Res. 1977 Mar;10(3):399–410. doi: 10.1016/0049-3848(77)90150-5. [DOI] [PubMed] [Google Scholar]
  13. Teunissen M. W., Meerburg-van der Torren J. E., Vermeulen N. P., Breimer D. D. Automated high-performance liquid chromatographic determination of antipyrine and its main metabolites in plasma, saliva and urine, including 4,4'-dihydroxyantipyrine. J Chromatogr. 1983 Dec 9;278(2):367–378. [PubMed] [Google Scholar]
  14. Vesell E. S. The antipyrine test in clinical pharmacology: conceptions and misconceptions. Clin Pharmacol Ther. 1979 Sep;26(3):275–286. doi: 10.1002/cpt1979263275. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES